Showing results (831-840 of 1,190) with videos related to
Sort By:
Pageof 119
Blood Advances|November 19, 2020
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemiaNicholas J Short, Guillermo Montalban-Bravo, Hyunsoo Hwang, et al.Journal of Clinical Medicine|January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 TrialEsther Natalie Oliva, Uwe Platzbecker, Guillermo Garcia-Manero, et al.Leukemia & Lymphoma|August 12, 2021
Clinical and molecular characterization of myeloid sarcoma without medullary leukemiaHussein A Abbas, Patrick K Reville, Alexis Geppner, et al.Acta Haematologica|May 12, 2020
Treating Leukemia in the Time of COVID-19Shilpa Paul, Caitlin R Rausch, Nitin Jain, et al.American Journal of Hematology|January 5, 2023
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up resultsHagop Kantarjian, Nicholas J Short, Nitin Jain, et al.American Journal of Hematology|January 23, 2023
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitorsElias J Jabbour, Koji Sasaki, Fadi G Haddad, et al.Cancer|June 23, 2021
Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromesRashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Koji Sasaki, et al.Cancer|March 13, 2019
Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndromeKiran Naqvi, Koji Sasaki, Guillermo Montalban-Bravo, et al.Cancer|April 8, 2017
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approachPrajwal Chaitanya Boddu, Hagop M Kantarjian, Farhad Ravandi, et al.The Lancet. Haematology|March 28, 2024
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trialAlexandre Bazinet, Hagop Kantarjian, Alex Bataller, et al.Pageof 119